CRGX

CARGO Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cargo-tx.com
Employees(FY) 42
ISIN US14179K1016

Performance

-73.99%

-73.84%

-82.99%

-78.7%

-75.03%

YTD

-83.64%

Profile

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Advanced Technical Analysis

Technical Analysis of CRGX 2025-01-30

The stock indicators reflect a bearish sentiment, with a Moving Average Score of 3, an Oscillators Score of 36, and a Technical Score of 10, indicating overall weakness in price momentum and trend direction. This combination suggests that the stock is currently underperforming and may face continued downward pressure.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CRGX

Stock Rank

Recent News & Updates

2025-01-30 06:24
Chardan Downgrades CARGO Therapeutics to Neutral From Buy, Withdraws $28 Price Target(MT Newswires)
2025-01-30 06:20
Truist Downgrades CARGO Therapeutics to Hold From Buy, Cuts Price Target to $7 From $32(MT Newswires)
2025-01-30 06:14
Cargo Therapeutics to Cut Workforce by 50%, Discontinue Lymphoma Treatment Study -- Shares Down Pre-Bell(MT Newswires)
2025-01-29 16:05
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options(GlobeNewswire)
2025-01-29 03:05
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options(Globenewswire)
2025-01-10 08:00
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025(GlobeNewswire)
2025-01-09 19:00
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025(Globenewswire)
2024-12-22 21:49
How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options(Prnewswire)
2024-12-17 08:00
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference(GlobeNewswire)
2024-12-16 19:00
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference(Globenewswire)
2024-12-16 18:34
Down -14.13% in 4 Weeks, Here's Why CARGO Therapeutics, Inc. (CRGX) Looks Ripe for a Turnaround(Zacks)
2024-12-12 09:55
Bears are Losing Control Over CARGO Therapeutics, Inc. (CRGX), Here's Why It's a 'Buy' Now(Zacks)
2024-11-26 08:01
William Blair Initiates CARGO Therapeutics at Outperform(MT Newswires)
2024-11-12 16:05
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update(GlobeNewswire)
2024-11-12 03:05
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-11-05 16:05
CARGO Therapeutics to Participate in Upcoming Investor Conferences(GlobeNewswire)
2024-11-05 09:23
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity(GlobeNewswire)
2024-11-05 03:05
CARGO Therapeutics to Participate in Upcoming Investor Conferences(Globenewswire)
2024-11-04 20:23
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma Activity(Globenewswire)
2024-10-18 10:06
Here's Why We're Not Too Worried About CARGO Therapeutics' (NASDAQ:CRGX) Cash Burn Situation(Simply Wall St.)
2024-08-16 18:50
Why Cargo Therapeutics Stock Rocketed Nearly 20% Higher This Week(Motley Fool)
2024-08-16 08:53
CRGX Stock Earnings: Cargo Therapeutics Beats EPS for Q2 2024(Investorplace)
2024-08-12 16:05
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update(GlobeNewswire)
2024-08-12 04:05
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-07-29 09:52
With 54% ownership of the shares, CARGO Therapeutics, Inc. (NASDAQ:CRGX) is heavily dominated by institutional owners(Simply Wall St.)
2024-07-22 08:14
HC Wainwright Initiates CARGO Therapeutics With Buy Rating, $33 Price Target(MT Newswires)
2024-07-10 08:00
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet(GlobeNewswire)
2024-07-09 20:00
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet(Globenewswire)
2024-06-04 16:05
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director(GlobeNewswire)
2024-06-04 04:05
CARGO Therapeutics Adds Experienced Biopharma Executive to Board of Directors with the Appointment of Jane Pritchett Henderson as Independent Director(Globenewswire)

Page 1 of 2

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.